profit from every ₹100 of sales.
₹0₹100
Nephrocare Health SERV L
₹630.40+1.67% today
+40.4% in 1 year
1-year low ₹449.151-year high ₹765.35
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2023 to 2026.
0%20% a year
You pay ₹82.50 for every ₹1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Nephrocare Health SERV L sold, what it kept, and what it did with the cash.
Sales went from ₹4.15 billion in 2023 to ₹9.99 billion in 2026, with ₹768 million of profit last year.
SalesProfit
Nephrocare Health SERV L vs. similar companies
Nephrocare Health SERV L grows in the middle of these 5 and is the most expensive for its profits.
| Company | Profit from ₹100 of sales | Sales growth a year | Price per ₹1 of profit |
|---|---|---|---|
| Nephrocare Health SERV L | 82.5× · Very expensive | ||
 HCA Healthcare | 15.6× · Fair price | ||
 Fresenius SE & Co. KGaA | 23.5× · Fair price | ||
 IHH Healthcare Berhad | 33.4× · Expensive | ||
 Rede D'Or São Luiz | 15.9× · Fair price |
AI analysis
An AI analyst reads Nephrocare Health SERV L's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| 4,145 | 5,396 | 7,558 | 9,988 | |
| 1,035 | 1,709 | 2,809 | 4,081 | |
| 36 | 535 | 942 | 1,363 | |
| 529 | 1,070 | 1,807 | 2,484 | |
| -118 | 351 | 671 | 768 | |
| -1.17 | 3.50 | 6.69 | 8.10 | |
| 25.0% | 31.7% | 37.2% | 40.9% | |
| 0.9% | 9.9% | 12.5% | 13.6% | |
| -2.8% | 6.5% | 8.9% | 7.7% |
Balance sheet
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Total assets | 6,662 | 8,060 | 9,965 | 14,709 |
| Cash | 132 | 612 | 1,258 | 1,239 |
| Total debt | 2,137 | 2,678 | 2,578 | 797 |
| Total liabilities | 2,776 | 3,923 | 4,123 | 3,544 |
| 3,886 | 4,137 | 5,841 | 11,165 | |
| 100 | 100 | 100 | 95 | |
| 0.7% | 5.7% | 9.6% | 9.9% | |
| -3.0% | 8.5% | 11.5% | 6.9% |
Cash flow
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| 113 | 723 | 1,353 | 2,326 | |
| 737 | 800 | 1,008 | 1,194 | |
| -625 | -77 | 346 | 1,132 | |
| Dividends paid | – | – | – | – |
| 33 | 0 | – | – | |
| 21 | 19 | 64 | 92 |
Valuation
- 82.5×
- –
- –
- 6.8×
- 6.3×
- 56.0×
- 25.3×
- 1.8%
- 1.2%
- –
Profitability
- 40.9%
- 13.6%
- 7.7%
- –
- 9.9%
- 6.5%
- –
- –
- –
- –
Growth
- +34.1%
- –
- –
- –
- −1.9%
Financial health
- -0.2×
- 0.07
- –
- 2.6×
- 2.80
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 30%of 958
Top 39%of 888
Bottom 13%of 600
Top 16%of 889
Top 45%of 987
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
44No pass
Benjamin Graham
29No pass
Philip Fisher
50No pass
Peter Lynch
85Pass
Joel Greenblatt
6No pass
Charlie Munger
43No pass
Terry Smith
46No pass
Questions about Nephrocare Health SERV L
Is Nephrocare Health SERV L a good stock to buy?
A business with weak numbers, priced as if everything goes right. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Nephrocare Health SERV L AI analysis
What does Nephrocare Health SERV L do?
Nephrocare Health Services Limited operates a chain of kidney care clinics that provides dialysis healthcare services with dialysis centres in India, Uzbekistan, Nepal, Kingdom of Saudi Arabia, and the Philippines. It is in Medical Care Facilities, based in Hyderabad, India.
Is Nephrocare Health SERV L stock halal?
Yes. Nephrocare Health SERV L passes our halal screen: its business is permitted and its debt is 1% of its market value, under the 30% limit. How we check
How has Nephrocare Health SERV L stock done over the past year?
Up 40.4% over the past twelve months, to ₹630.40. It traded between ₹449.15 and ₹765.35 and is 17.6% below its high.
Who are Nephrocare Health SERV L's competitors?
The largest listed companies in the same industry are HCA Healthcare, Fresenius SE & Co. KGaA, IHH Healthcare Berhad and Rede D'Or São Luiz. The peers table on this page compares their profit, growth and price with Nephrocare Health SERV L's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.